Search Results

Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM).

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, announced the closing of its merger with Biosight, Ltd., pursuant to which Ayala acquired Biosight.

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, announced that it filed a Form 15 with the Securities and Exchange Commission to deregister its common stock under Section 12 of the Securities Exchange Act of 1934, as amended, and to suspend its reporting obligations under Section 15 of the Exchange Act.

Immunome, Inc. today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, to acquire AL102.

Ayala Pharmaceuticals, Inc. and Biosight Ltd. today announced they have entered into a definitive merger agreement pursuant to which Ayala will combine with Biosight in an all-stock transaction.

Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors.

Immunome, Inc. today recognized the announcement by Ayala Pharmaceuticals, Inc. that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors.

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, to acquire AL102 and related drug candidate AL101 from Ayala.

Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AL102, a Gamma Secretase Inhibitor (GSI), for the treatment of desmoid tumors (DT).